A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Alpelisib (Primary) ; Elgemtumab (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 24 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 24 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 07 Jan 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017, according to ClinicalTrials.gov record.